ARROWHEAD RESEARCH AGREES TO PROVIDE $10 MILLION ADDITIONAL FUNDING FOR CALANDO PHARMACEUTICALS

Arrowhead Research Corporation announced that it has agreed to contribute up to $10 million in additional capital to its majority-owned subsidiary, Calando Pharmaceuticals, Inc. The additional capital will allow Calando to accelerate preclinical testing of its RNAi therapeutics and to facilitate additional collaborations with large biotech and pharmaceutical companies. Small Times (http://www.smalltimes.com/document_display.cfm?section_id=51&document_id=11164)